Adicet Bio, Inc. Net Income (Loss) Available to Common Stockholders, Diluted
Adicet Bio, Inc. (ACET) reported Net Income (Loss) Available to Common Stockholders, Diluted of -$21.36 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Income Statement › Net Income
us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted · last filed 2026-08-05
- Adicet Bio, Inc. net income (loss) available to common stockholders, diluted for the quarter ending 2026-06-30 was -$21.36M.
- Adicet Bio, Inc. net income (loss) available to common stockholders, diluted for the quarter ending 2026-03-31 was -$20.24M.
- Adicet Bio, Inc. net income (loss) available to common stockholders, diluted for the quarter ending 2025-12-31 was -$30.52M.
- Adicet Bio, Inc. net income (loss) available to common stockholders, diluted for the quarter ending 2025-09-30 was -$26.86M.
- Adicet Bio, Inc. net income (loss) available to common stockholders, diluted for fiscal 2025 was -$116.80M.
- Adicet Bio, Inc. net income (loss) available to common stockholders, diluted for fiscal 2024 was -$117.12M.
| Period end | Net Income (Loss) Available to Common Stockholders, Diluted 3 month | Net Income (Loss) Available to Common Stockholders, Diluted 6 month | Net Income (Loss) Available to Common Stockholders, Diluted 9 month | Net Income (Loss) Available to Common Stockholders, Diluted 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$21.36M 10-Q · filed 2026-08-05 | -$41.60M 10-Q · filed 2026-08-05 | -$72.12M derived: sum of 3 quarters · filed 2026-08-05 | -$98.97M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | -$20.24M 10-Q · filed 2026-05-13 | -$50.76M derived: sum of 2 quarters · filed 2026-05-13 | -$77.62M derived: sum of 3 quarters · filed 2026-05-13 | -$108.83M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | -$30.52M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | -$57.37M derived: sum of 2 quarters · filed 2026-03-12 | -$88.59M derived: sum of 3 quarters · filed 2026-08-05 | -$116.80M 10-K · filed 2026-03-12 |
| 2025-09-30 | -$26.86M 10-Q · filed 2025-11-05 | -$58.07M derived: sum of 2 quarters · filed 2026-08-05 | -$86.29M 10-Q · filed 2025-11-05 | -$115.01M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | -$31.22M 10-Q · filed 2026-08-05 | -$59.43M 10-Q · filed 2026-08-05 | -$88.16M derived: sum of 3 quarters · filed 2026-08-05 | -$118.64M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | -$28.21M 10-Q · filed 2026-05-13 | -$56.94M derived: sum of 2 quarters · filed 2026-05-13 | -$87.42M derived: sum of 3 quarters · filed 2026-05-13 | |
| 2024-12-31 | -$28.73M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | -$59.20M derived: sum of 2 quarters · filed 2026-03-12 | -$117.12M 10-K · filed 2026-03-12 | |
| 2024-09-30 | -$30.48M 10-Q · filed 2025-11-05 | -$88.39M 10-Q · filed 2025-11-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |